[go: up one dir, main page]

MX2019013033A - Formulaciones estables de anticuerpos anti-tigit solos y en combinacion con anticuerpos anti-receptor de muerte programada 1 (pd-1) y metodos para su uso. - Google Patents

Formulaciones estables de anticuerpos anti-tigit solos y en combinacion con anticuerpos anti-receptor de muerte programada 1 (pd-1) y metodos para su uso.

Info

Publication number
MX2019013033A
MX2019013033A MX2019013033A MX2019013033A MX2019013033A MX 2019013033 A MX2019013033 A MX 2019013033A MX 2019013033 A MX2019013033 A MX 2019013033A MX 2019013033 A MX2019013033 A MX 2019013033A MX 2019013033 A MX2019013033 A MX 2019013033A
Authority
MX
Mexico
Prior art keywords
antibodies
methods
programmed death
death receptor
combination
Prior art date
Application number
MX2019013033A
Other languages
English (en)
Inventor
De Arnab
Nachu Narasimhan Chakravarthy
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=64016405&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2019013033(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MX2019013033A publication Critical patent/MX2019013033A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a formulaciones estables de anticuerpos contra receptores de linfocitos T con dominios lg e ITIM (TIGIT), que opcionalmente además contienen un anticuerpo anti receptor de muerte programada 1 humana (PD-1) o un fragmento de fijación al antígeno de este. También se proporcionan métodos para tratar varios tipos de cáncer e infecciones crónicas con las formulaciones de la invención.
MX2019013033A 2017-05-02 2018-05-01 Formulaciones estables de anticuerpos anti-tigit solos y en combinacion con anticuerpos anti-receptor de muerte programada 1 (pd-1) y metodos para su uso. MX2019013033A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762500278P 2017-05-02 2017-05-02
PCT/US2018/030516 WO2018204405A1 (en) 2017-05-02 2018-05-01 Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2019013033A true MX2019013033A (es) 2020-02-05

Family

ID=64016405

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019013033A MX2019013033A (es) 2017-05-02 2018-05-01 Formulaciones estables de anticuerpos anti-tigit solos y en combinacion con anticuerpos anti-receptor de muerte programada 1 (pd-1) y metodos para su uso.

Country Status (15)

Country Link
US (2) US20200354453A1 (es)
EP (1) EP3618855A4 (es)
JP (2) JP7402693B2 (es)
KR (1) KR102770786B1 (es)
CN (1) CN110603052A (es)
AU (1) AU2018261080A1 (es)
BR (1) BR112019022698A2 (es)
CA (1) CA3061050A1 (es)
CL (1) CL2019003145A1 (es)
CO (1) CO2019012356A2 (es)
IL (1) IL270175B2 (es)
MA (1) MA50661A (es)
MX (1) MX2019013033A (es)
SG (2) SG11201909941QA (es)
WO (1) WO2018204405A1 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ600758A (en) 2007-06-18 2013-09-27 Merck Sharp & Dohme Antibodies to human programmed death receptor pd-1
US10766957B2 (en) * 2015-08-14 2020-09-08 Merck Sharp & Dohme Corp Anti-TIGIT antibodies
TW202402800A (zh) 2017-05-01 2024-01-16 美商艾吉納斯公司 抗ｔｉｇｉｔ抗體類和使用彼等之方法
SG11201909955XA (en) 2017-05-02 2019-11-28 Merck Sharp & Dohme Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
IL277095B2 (en) * 2018-03-07 2025-10-01 Pfizer Preparations containing anti-PD-1 antibody
EP3876990A4 (en) 2018-11-07 2023-09-06 Merck Sharp & Dohme LLC CO-FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES
US20210380694A1 (en) * 2018-11-07 2021-12-09 Merck Sharp & Dohme Corp. Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
EP3893841A1 (en) * 2018-12-14 2021-10-20 MorphoSys AG Antibody formulations
BR112021022171A2 (pt) * 2019-06-13 2021-12-21 Green Cross Corp Anticorpo para tigit, seu uso e método para produzir o mesmo
US20220273796A1 (en) * 2019-07-19 2022-09-01 Ichnos Sciences SA Lyophilized antibody formulation
CN112741804A (zh) * 2019-10-31 2021-05-04 上海君实生物医药科技股份有限公司 含有抗pd-l1抗体的稳定制剂
EP4094777A4 (en) * 2020-01-21 2024-01-24 Innovent Biologics (Suzhou) Co., Ltd. PREPARATIONS OF FULLY HUMAN RECOMBINANT ANTI-TIGIT MONOCLONAL ANTIBODIES, METHOD FOR PREPARING THE SAME AND THEIR USE
KR20220131923A (ko) * 2020-01-24 2022-09-29 리제너론 파마슈티칼스 인코포레이티드 안정한 항체 제형
CN114507284B (zh) * 2020-05-09 2023-05-26 华博生物医药技术（上海）有限公司 抗tigit的抗体、其制备方法和应用
CR20220611A (es) * 2020-06-02 2023-06-07 Arcus Biosciences Inc Anticuerpos anti-tigit
US20210395366A1 (en) 2020-06-18 2021-12-23 Genentech, Inc. Treatment with anti-tigit antibodies and pd-1 axis binding antagonists
CN111718415B (zh) * 2020-07-03 2021-02-23 上海洛启生物医药技术有限公司 一种抗tigit纳米抗体及其应用
TW202216778A (zh) 2020-07-15 2022-05-01 美商安進公司 Ｔｉｇｉｔ及ｃｄ１１２ｒ阻斷
RS66849B1 (sr) * 2020-12-28 2025-06-30 Bristol Myers Squibb Co Kompozicije antitela i postupci njihove upotrebe
EP4293045A4 (en) * 2021-01-14 2024-12-11 Shanghai Junshi Biosciences Co., Ltd. PHARMACEUTICAL COMPOSITION OF ANTI-TIGIT ANTIBODY AND ITS APPLICATION
EP4284834A1 (en) 2021-01-29 2023-12-06 Merck Sharp & Dohme LLC Compositions of programmed death receptor 1 (pd-1) antibodies and methods of obtaining the compositions thereof
AR125753A1 (es) 2021-05-04 2023-08-09 Agenus Inc Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos
AU2022314097A1 (en) * 2021-07-23 2024-03-07 Akeso Biopharma, Inc Pharmaceutical composition and use
JP2024527049A (ja) 2021-07-28 2024-07-19 ジェネンテック， インコーポレイテッド がんを治療するための方法及び組成物
TW202321308A (zh) 2021-09-30 2023-06-01 美商建南德克公司 使用抗ｔｉｇｉｔ抗體、抗ｃｄ３８抗體及ｐｄ—１軸結合拮抗劑治療血液癌症的方法
CN114106182B (zh) * 2022-01-26 2022-05-17 中山康方生物医药有限公司 抗tigit的抗体及其用途
AU2023252259A1 (en) * 2022-04-14 2024-11-07 Beigene Switzerland Gmbh Stable high concentration arginine formulations containing pd-1 antibody and methods of use thereof
JP2025523387A (ja) 2022-06-07 2025-07-23 ジェネンテック， インコーポレイテッド 抗ｐｄ－ｌ１アンタゴニストおよび抗ｔｉｇｉｔアンタゴニスト抗体を含む、肺がん治療の有効性を判定するための方法
EP4565614A2 (en) * 2022-08-04 2025-06-11 Merck Sharp & Dohme LLC Methods for determining one or more critical quality attributes of co-formulated antibodies
KR20250124247A (ko) * 2022-12-27 2025-08-19 상하이 헨리우스 바이오테크, 인크. 항-tigit 항체를 포함하는 약학적 제제
WO2025166550A1 (zh) * 2024-02-06 2025-08-14 香港北恒生物科技有限公司 工程化细胞及其用途
CN121003695A (zh) * 2024-05-24 2025-11-25 百奥泰生物制药股份有限公司 抗tigit抗体和抗pd-1抗体联合治疗肿瘤
WO2025248110A1 (en) 2024-05-31 2025-12-04 Replimune Limited An oncolytic herpes simplex virus (hsv) and an anti-pd-1 antibody for use in treating braf mutant melanoma

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20081179A1 (es) * 2006-10-06 2008-09-29 Amgen Inc Formulaciones estables de anticuerpos egfr
EP2453874A2 (en) * 2009-07-14 2012-05-23 Biogen Idec MA Inc. Methods for inhibiting yellow color and peroxide formation in a composition
EP2399604A1 (en) * 2010-06-25 2011-12-28 F. Hoffmann-La Roche AG Novel antibody formulation
US9220776B2 (en) * 2011-03-31 2015-12-29 Merck Sharp & Dohme Corp. Stable formulations of antibodies to human programmed death receptor PD-1 and related treatments
WO2014031718A1 (en) * 2012-08-23 2014-02-27 Merck Sharp & Dohme Corp. Stable formulations of antibodies to tslp
DK3021869T3 (da) * 2013-07-16 2020-09-21 Hoffmann La Roche Fremgangsmåder til behandling af cancer ved anvendelse af PD-1-aksebindende antagonister og TIGIT-hæmmere
KR102050082B1 (ko) * 2014-08-19 2019-11-29 머크 샤프 앤드 돔 코포레이션 항-tigit 항체
SG10202006538TA (en) * 2014-12-23 2020-08-28 Bristol Myers Squibb Co Antibodies to tigit
AU2016322934A1 (en) * 2015-09-14 2018-04-12 Compass Therapeutics Llc Compositions and methods for treating cancer via antagonism of the CD155/TIGIT pathway and TGF-beta
WO2017112621A1 (en) * 2015-12-22 2017-06-29 Merck Sharp & Dohme Corp. Formulations of engineered anti-il-10 antibodies
JP2019514889A (ja) * 2016-04-25 2019-06-06 メディミューン，エルエルシー 抗ｐｄ−ｌ１および抗ｃｔｌａ−４抗体の共製剤を含む組成物
MA50501A (fr) * 2017-05-02 2020-09-09 Merck Sharp & Dohme Formulations stables d'anticorps anti-ctla4 seuls et en combinaison avec des anticorps anti-récepteur de mort programmée 1 (pd-1) et leurs procédés d'utilisation

Also Published As

Publication number Publication date
RU2019138519A3 (es) 2021-08-30
EP3618855A1 (en) 2020-03-11
JP2020518600A (ja) 2020-06-25
WO2018204405A1 (en) 2018-11-08
US20240182573A1 (en) 2024-06-06
AU2018261080A1 (en) 2019-11-07
JP2024016177A (ja) 2024-02-06
RU2019138519A (ru) 2021-06-02
CL2019003145A1 (es) 2020-07-10
CA3061050A1 (en) 2018-11-08
SG10202111905PA (en) 2021-12-30
CN110603052A (zh) 2019-12-20
MA50661A (fr) 2020-08-05
BR112019022698A2 (pt) 2020-05-19
IL270175B1 (en) 2023-05-01
JP7402693B2 (ja) 2023-12-21
EP3618855A4 (en) 2021-02-17
CO2019012356A2 (es) 2020-01-17
IL270175A (es) 2019-12-31
US20200354453A1 (en) 2020-11-12
KR20190142394A (ko) 2019-12-26
IL270175B2 (en) 2023-09-01
SG11201909941QA (en) 2019-11-28
KR102770786B1 (ko) 2025-02-20

Similar Documents

Publication Publication Date Title
MX2019013033A (es) Formulaciones estables de anticuerpos anti-tigit solos y en combinacion con anticuerpos anti-receptor de muerte programada 1 (pd-1) y metodos para su uso.
TN2019000294A1 (en) Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
PH12019502463A1 (en) Anti-cd33 antibodies and methods of use thereof
MX392369B (es) Anticuerpos anti-ilt4 y fragmentos de union a antigeno.
CR20200467A (es) Agentes anticuerpos anti-cd25
MX2023006212A (es) Anticuerpos anti inmunorreceptor de linfocitos t con dominios de motivo de inactivacion basado en tirosina de inmunorreceptor e inmunoglobulina (tigit).
MX2021015888A (es) Fusión de un anticuerpo que se une a cea y 4-1bbl.
MX2021013681A (es) Moleculas de union a lag-3 y metodos de uso de las mismas.
MX2024007724A (es) Conjugados de farmaco-anticuerpo anti-antigeno de membrana especifico de prostata (psma) humanizado
EA201891428A1 (ru) Комбинация антител к pd-1 и биспецифических антител к cd20/cd3 для лечения злокачественной опухоли
PH12018500295B1 (en) Chimeric antigen receptors based on single-domain antibodies and methods of use thereof
EA201991156A1 (ru) АНТИТЕЛА К Tim-3 ДЛЯ КОМБИНАЦИИ С АНТИТЕЛАМИ К PD-1
WO2017075432A3 (en) Anti-siglec-9 antibodies and methods of use thereof
WO2016201389A3 (en) Anti-cd33 antibodies and methods of use thereof
WO2016201388A3 (en) Anti-cd33 antibodies and methods of use thereof
EP3991748A3 (en) Anti-sortilin antibodies and methods of use thereof
PH12021551498A1 (en) Activatable masked anti-ctla4 binding proteins
MX2015004105A (es) Anticuerpos monoclonales humanos anti-pd-l1 y metodos de uso.
MX2020009468A (es) Terapias de combinacion de agonistas de 4-1bb con anticuerpos anti-cd20.
EA201791691A1 (ru) ОДНОДОМЕННЫЕ АНТИТЕЛА, НАПРАВЛЕННЫЕ НА CD1d
PH12020551323A1 (en) Anti cd6 antibodies for treating severe asthma
NZ756585A (en) Anti-ceacam1 antibody and use thereof
MX2020009864A (es) Anticuerpos anti-cd137 para combinacion con anticuerpos anti-pd-1.
MX2020009863A (es) Anticuerpos anti-cd137 para combinacion con anticuerpos anti-pd-l1.
WO2020186158A3 (en) Prame binding molecules and uses thereof